Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Dominique P Germain, Joel Charrow, Robert J Desnick...
https://pubmed.ncbi.nlm.nih.gov/25795794/Actively Recruiting
Led by Genzyme, a Sanofi Company · Updated on 2026-10-14
9000
Participants Needed
284
Research Sites
N/A
Total Duration
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
CONDITIONS
Fabry Disease Registry & Pregnancy Sub-registry
T
Trial Transparency
F
Fabry Registry HelpLine
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Genzyme, a Sanofi Company
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 33 years
Participants undergo routine clinical assessments and receive standard care as determined by their physicians. Data on health outcomes, treatment safety, and pregnancy details are collected over time without experimental treatments.
Regular clinical assessments as per usual care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dominique P Germain, Joel Charrow, Robert J Desnick...
https://pubmed.ncbi.nlm.nih.gov/25795794/William R Wilcox, Ulla Feldt-Rasmussen, Ana Maria Martins...
https://pubmed.ncbi.nlm.nih.gov/28510034/Robert J Hopkin, Gustavo Cabrera, Joel Charrow...
https://pubmed.ncbi.nlm.nih.gov/27510433/Robert J Hopkin, Gustavo H Cabrera, John L Jefferies...
https://pubmed.ncbi.nlm.nih.gov/36709533/Dominique P Germain, Eva Brand, Alessandro Burlina...
https://pubmed.ncbi.nlm.nih.gov/29649853/Christoph Wanner, Ulla Feldt-Rasmussen, Alberto Ortiz
https://pubmed.ncbi.nlm.nih.gov/36073247/Alberto Ortiz, Ademola Abiose, Daniel G Bichet...
https://pubmed.ncbi.nlm.nih.gov/26993266/Genzyme, a Sanofi Company
Lead Sponsor